Clinical trials
catalyst calendar across sponsors →Studies where INGN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional
Held by 8 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, Point72 Asset Management, L.P., D. E. Shaw & Co., Inc., MILLENNIUM MANAGEMENT LLC, +3 more) · FINRA short interest 6.3 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Simeox 200 US StudyNCT07443124Wet sputum weight collected with Simeox 200 during device training visitOpen-label · Treatment | Not applicable | Not yet recruiting | Device: Intermittent intrapulmonary deflation | Bronchiectasis, Mucus; Plug | 35 | May 2026 | 2026-03-02 |
| Acute Effects of Supplemental Oxygen on Memory Testing in Healthy Adult VolunteersNCT065554842 back Memory test performanceRandomized · Double-masked · Basic science | Not applicable | Completed | Device: Cross Over Assignment Supplemental Oxygen and Supplemental Air | Cognition | 40 | 2024-10-31actual | 2025-01-31 |
| Evaluation of POC Pulse-dose Demand Oxygen Delivery for Nocturnal HypoxemiaNCT06000332Number/% of subjects that could achieve SpO2 ≥90% for >30% of sleep timeOpen-label · Treatment | Not applicable | Completed | Device: InogenOne Rove 6 Portable Oxygen Concentrator | Nocturnal Hypoxemia | 20 | 2023-12-21actual | 2024-01-05 |
| Portable Oxygen Concentrator in Non-hospitalized Patients With Chronic Heart FailureNCT05719363Walking distance during the 6MWTRandomized · Single-masked · Supportive care | Not applicable | Completed | Device: Inogen Rove 6 Portable Oxygen Concentrator | Heart Failure | 20 | 2023-11-21actual | 2024-01-03 |
| Portable Oxygen Concentrator (POC) Versus Standard of Care in Long-COVID: Randomized Crossover Exploratory Pilot Study.NCT05212831COVID-19 related brain hypoxia and peripheral oxygen saturationRandomized · Open-label · Treatment | Not applicable | Completed | Device: Inogen One® G4 | COVID-19 | 21 | 2023-03-02actual | 2023-07-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19